Minutes - Medication WG 2022-02-15

From Health Level 7 Belgium Wiki
Attendees
  • An Crepel, digile
  • Annemieke Vergauwe
  • Bart Decuypere
  • Jan Lenie
  • Jean-Michel Polfliet
  • Jens Penny
  • José Costa Teixeira
  • Karlien Erauw
  • Kris Deceunynck
  • Pablo Christiaens
  • Thomas Van Langendonck
  • Tom Henkens
Excused/Not present
  • Anne Nerenhausen
  • Bruno Casneuf
  • Dieter Sauvillers
  • Elhassan Baazizi
  • Hanne Vuegen
  • Jean-Louis Maggetto
  • Jeroen De Wilde
  • Katrien Thorré
  • Lars Vanreppelen
  • Marc Buckens
  • Nick Hermans
  • Nils Devos
  • Richard Francken
  • Thomas Van Langendonck
  • Tom De Backer
  • Walter Bollaert
  • Will van Norel
Agenda
  • discussion on drug databaes
  • review of prepared use cases
Minutes
  • An from Digile has worked on the SAM database and has plenty of drug data expertise
  • BCFI, the green booklet used by pharmacists & doctors
  • BCFI was structured in a Repertorium drug tables
  • SAM is a consortium: APB, RIZIV, FOD VG, FAGG to put all drugs in one database
  • VMP, VMP-groups are concepts were implemented through guidance from BCFI
  • public SAM viewer was developed by Digile, visualisation in an intuitive manner that has the full SAMv2 content (2 updates a day - not realtime), is public
  • feedback option is available as there are still some data quality issues & inconsistencies with SAM
  • difficult follow-up on raised issues
  • overview of VOs-groups to improve easier access to these data that was not open to the public before
  • ISO IDMP gap analysis on SAM V2 has been done
  • ISO IDMP does not present a fixed vocabulary
  • objective is to map SAMv2 to ISO IDMP database, works quite well although there are no identifiers in the 2 sytems
  • attributes can be useful for the mapping
  • How can we query with FHIR on SAMv2 ?
  • Concept of VMP group: it is a clinical concept
  • to add
  • VMP is more a regulatory concept
  • our WG goal: how to represent medication in a medication scheme - which recommendation is there ? current MS is focused on brand name, VOS-group of substance seems better from a clinical point of view of VMP-group as it includes the route of administration
  • RIZIV wants a different view so both levels will have to be there (packages)



  • VIDIS would like to have first artefacts of our WG
  • medication treatment line are being worked on


Action items for next meeting

  • José to work on use cases and add medication view line in view and how it all works at operational level
  • Jens to start writing up document

Next meeting March 1 at 11AM